Baricitinib patent expiry?

Baricitinib (Olumiant®) – Patent Landscape Overview

Baricitinib is a Janus‑kinase (JAK) 1/2 inhibitor used primarily for rheumatoid arthritis, COVID‑19, and other inflammatory conditions. Eli Lilly & Co. holds a portfolio of patents covering the drug’s composition, formulation, manufacturing process, and therapeutic uses. Below is a snapshot of the key patents that have defined the drug’s exclusivity window and their current status.

Key take‑aways:

• The primary composition patent (US 8,381,292) expires in November 2025.
• The method‑of‑use and formulation patents extend the protection to mid‑2026.
• The EU patent expires one year earlier, in January 2024.
• Data exclusivity in the U.S. (5 years from FDA approval) ended in 2018 + 5 = 2023, so generic manufacturers could file BLA (generic) applications after 2023, but the patents must still be valid.

When Can Generics Enter the Market?

1. Data exclusivity (5 years for small molecules) ended in 2023.
2. Patent protection continues until 2025–2026.
3. Generic entry typically follows the last expiring patent, so the earliest realistic entry for a generic Baricitinib in the U.S. would be late 2026 or early 2027, assuming no additional patents (e.g., “ever‑green” extensions) or regulatory hurdles.
4. In the EU, generics would have to wait until post‑January 2024 for the EU patent, but would still need to navigate market exclusivity granted for the original drug (usually 8–12 years from approval, ending around 2030).

If you’re planning to market a generic, it’s crucial to perform a full patent landscape search and confirm that no “ever‑green” extensions or additional “secondary” patents (e.g., formulation, delivery system) are still in force.

How to Keep Up‑to‑Date

• PatentWatch or LexisNexis databases provide real‑time updates on patent expirations.
• The FDA’s Orange Book lists the approved drug’s exclusivity period and any pending “generic” filings.
• In the EU, the European Medicines Agency (EMA) publishes the “Exclusivity” periods for each medicinal product.

Bottom line:
The core patents on Baricitinib (Olumiant) will likely expire by late 2025–2026 (U.S.) and early 2024 (EU). Generic competition is expected to start late 2026 in the U.S., assuming no further extensions. For the most accurate, real‑time data, always consult a specialized patent attorney or the official patent databases.